The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung

evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center

Alberto M. Marchevsky, Nolwenn LeStang, Kenzo Hiroshima, Giuseppe Pelosi, Richard Attanoos, Andrew Churg, Lucian Chirieac, Sanja Dacic, Aliya Husain, Andras Khoor, Sonja Klebe, Silvie Lantuejoul, Victor Roggli, Jean Michel Vignaud, Birgit Weynard, Jennifer Sauter, Douglas Henderson, Kasuzi Nabeshima, Francoise Galateau-Salle

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Immunohistochemistry is used to distinguish sarcomatoid malignant mesotheliomas (SMM) from spindle cell and pleomorphic carcinomas (SPC) but there are no guidelines on how to interpret cases that show overlapping or equivocal immunohistochemical findings. A systematic literature review of the immunophenotype of these lesions was performed and the experience with 587 SMM and 46 SPC at MESOPATH was collected. Data were analyzed with Comprehensive Meta-Analysis 2.0 software (Biostat, Englewood, NJ). There were insufficient data to evaluate the differential diagnosis between SPC and localized SMM or peritoneal SMM. Meta-analysis showed considerable overlap in the immunophenotype of these neoplasms and significant data heterogeneity amongst many of the results. Survival data from MESOPATH patients showed no significant differences in overall survival between SMM and SPC patients. Best available evidence was used to formulate several evidence-based guidelines for the differential diagnosis between pleural SMM and SPC. These guidelines emphasize the need to correlate the histopathological findings with clinical and imaging information. Diffuse SMM can be diagnosed with certainty in the presence of malignant spindle cell pleural lesions showing immunoreactivity for cytokeratin and mesothelial markers and negative staining for epithelial markers. Criteria for the interpretation of various other combinations of immunoreactivity for cytokeratin and mesothelial and/or epithelial markers are proposed. Localized sarcomatoid mesotheliomas can only be diagnosed in the presence of spindle cell malignancies that exhibit immunoreactivity for cytokeratin and mesothelial markers and negative immunoreactivity for epithelial lesions, in patients that show no multifocal or diffuse pleural spread and no evidence for extrapleural lesions.

Original languageEnglish (US)
Pages (from-to)160-168
Number of pages9
JournalHuman Pathology
Volume67
DOIs
StatePublished - Sep 1 2017

Fingerprint

Mesothelioma
Differential Diagnosis
Guidelines
Carcinoma
Lung
Keratins
Meta-Analysis
Pleural Solitary Fibrous Tumor
Negative Staining
Survival
Malignant Mesothelioma
Neoplasms
Software
Immunohistochemistry

Keywords

  • Differential diagnosis
  • Guidelines
  • Pleomorphic carcinoma
  • Sarcomatoid mesothelioma
  • Spindle cell carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung : evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. / Marchevsky, Alberto M.; LeStang, Nolwenn; Hiroshima, Kenzo; Pelosi, Giuseppe; Attanoos, Richard; Churg, Andrew; Chirieac, Lucian; Dacic, Sanja; Husain, Aliya; Khoor, Andras; Klebe, Sonja; Lantuejoul, Silvie; Roggli, Victor; Vignaud, Jean Michel; Weynard, Birgit; Sauter, Jennifer; Henderson, Douglas; Nabeshima, Kasuzi; Galateau-Salle, Francoise.

In: Human Pathology, Vol. 67, 01.09.2017, p. 160-168.

Research output: Contribution to journalArticle

Marchevsky, AM, LeStang, N, Hiroshima, K, Pelosi, G, Attanoos, R, Churg, A, Chirieac, L, Dacic, S, Husain, A, Khoor, A, Klebe, S, Lantuejoul, S, Roggli, V, Vignaud, JM, Weynard, B, Sauter, J, Henderson, D, Nabeshima, K & Galateau-Salle, F 2017, 'The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center', Human Pathology, vol. 67, pp. 160-168. https://doi.org/10.1016/j.humpath.2017.07.015
Marchevsky, Alberto M. ; LeStang, Nolwenn ; Hiroshima, Kenzo ; Pelosi, Giuseppe ; Attanoos, Richard ; Churg, Andrew ; Chirieac, Lucian ; Dacic, Sanja ; Husain, Aliya ; Khoor, Andras ; Klebe, Sonja ; Lantuejoul, Silvie ; Roggli, Victor ; Vignaud, Jean Michel ; Weynard, Birgit ; Sauter, Jennifer ; Henderson, Douglas ; Nabeshima, Kasuzi ; Galateau-Salle, Francoise. / The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung : evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. In: Human Pathology. 2017 ; Vol. 67. pp. 160-168.
@article{515c6a89b03340238a24df6d7a935a51,
title = "The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center",
abstract = "Immunohistochemistry is used to distinguish sarcomatoid malignant mesotheliomas (SMM) from spindle cell and pleomorphic carcinomas (SPC) but there are no guidelines on how to interpret cases that show overlapping or equivocal immunohistochemical findings. A systematic literature review of the immunophenotype of these lesions was performed and the experience with 587 SMM and 46 SPC at MESOPATH was collected. Data were analyzed with Comprehensive Meta-Analysis 2.0 software (Biostat, Englewood, NJ). There were insufficient data to evaluate the differential diagnosis between SPC and localized SMM or peritoneal SMM. Meta-analysis showed considerable overlap in the immunophenotype of these neoplasms and significant data heterogeneity amongst many of the results. Survival data from MESOPATH patients showed no significant differences in overall survival between SMM and SPC patients. Best available evidence was used to formulate several evidence-based guidelines for the differential diagnosis between pleural SMM and SPC. These guidelines emphasize the need to correlate the histopathological findings with clinical and imaging information. Diffuse SMM can be diagnosed with certainty in the presence of malignant spindle cell pleural lesions showing immunoreactivity for cytokeratin and mesothelial markers and negative staining for epithelial markers. Criteria for the interpretation of various other combinations of immunoreactivity for cytokeratin and mesothelial and/or epithelial markers are proposed. Localized sarcomatoid mesotheliomas can only be diagnosed in the presence of spindle cell malignancies that exhibit immunoreactivity for cytokeratin and mesothelial markers and negative immunoreactivity for epithelial lesions, in patients that show no multifocal or diffuse pleural spread and no evidence for extrapleural lesions.",
keywords = "Differential diagnosis, Guidelines, Pleomorphic carcinoma, Sarcomatoid mesothelioma, Spindle cell carcinoma",
author = "Marchevsky, {Alberto M.} and Nolwenn LeStang and Kenzo Hiroshima and Giuseppe Pelosi and Richard Attanoos and Andrew Churg and Lucian Chirieac and Sanja Dacic and Aliya Husain and Andras Khoor and Sonja Klebe and Silvie Lantuejoul and Victor Roggli and Vignaud, {Jean Michel} and Birgit Weynard and Jennifer Sauter and Douglas Henderson and Kasuzi Nabeshima and Francoise Galateau-Salle",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.humpath.2017.07.015",
language = "English (US)",
volume = "67",
pages = "160--168",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung

T2 - evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center

AU - Marchevsky, Alberto M.

AU - LeStang, Nolwenn

AU - Hiroshima, Kenzo

AU - Pelosi, Giuseppe

AU - Attanoos, Richard

AU - Churg, Andrew

AU - Chirieac, Lucian

AU - Dacic, Sanja

AU - Husain, Aliya

AU - Khoor, Andras

AU - Klebe, Sonja

AU - Lantuejoul, Silvie

AU - Roggli, Victor

AU - Vignaud, Jean Michel

AU - Weynard, Birgit

AU - Sauter, Jennifer

AU - Henderson, Douglas

AU - Nabeshima, Kasuzi

AU - Galateau-Salle, Francoise

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Immunohistochemistry is used to distinguish sarcomatoid malignant mesotheliomas (SMM) from spindle cell and pleomorphic carcinomas (SPC) but there are no guidelines on how to interpret cases that show overlapping or equivocal immunohistochemical findings. A systematic literature review of the immunophenotype of these lesions was performed and the experience with 587 SMM and 46 SPC at MESOPATH was collected. Data were analyzed with Comprehensive Meta-Analysis 2.0 software (Biostat, Englewood, NJ). There were insufficient data to evaluate the differential diagnosis between SPC and localized SMM or peritoneal SMM. Meta-analysis showed considerable overlap in the immunophenotype of these neoplasms and significant data heterogeneity amongst many of the results. Survival data from MESOPATH patients showed no significant differences in overall survival between SMM and SPC patients. Best available evidence was used to formulate several evidence-based guidelines for the differential diagnosis between pleural SMM and SPC. These guidelines emphasize the need to correlate the histopathological findings with clinical and imaging information. Diffuse SMM can be diagnosed with certainty in the presence of malignant spindle cell pleural lesions showing immunoreactivity for cytokeratin and mesothelial markers and negative staining for epithelial markers. Criteria for the interpretation of various other combinations of immunoreactivity for cytokeratin and mesothelial and/or epithelial markers are proposed. Localized sarcomatoid mesotheliomas can only be diagnosed in the presence of spindle cell malignancies that exhibit immunoreactivity for cytokeratin and mesothelial markers and negative immunoreactivity for epithelial lesions, in patients that show no multifocal or diffuse pleural spread and no evidence for extrapleural lesions.

AB - Immunohistochemistry is used to distinguish sarcomatoid malignant mesotheliomas (SMM) from spindle cell and pleomorphic carcinomas (SPC) but there are no guidelines on how to interpret cases that show overlapping or equivocal immunohistochemical findings. A systematic literature review of the immunophenotype of these lesions was performed and the experience with 587 SMM and 46 SPC at MESOPATH was collected. Data were analyzed with Comprehensive Meta-Analysis 2.0 software (Biostat, Englewood, NJ). There were insufficient data to evaluate the differential diagnosis between SPC and localized SMM or peritoneal SMM. Meta-analysis showed considerable overlap in the immunophenotype of these neoplasms and significant data heterogeneity amongst many of the results. Survival data from MESOPATH patients showed no significant differences in overall survival between SMM and SPC patients. Best available evidence was used to formulate several evidence-based guidelines for the differential diagnosis between pleural SMM and SPC. These guidelines emphasize the need to correlate the histopathological findings with clinical and imaging information. Diffuse SMM can be diagnosed with certainty in the presence of malignant spindle cell pleural lesions showing immunoreactivity for cytokeratin and mesothelial markers and negative staining for epithelial markers. Criteria for the interpretation of various other combinations of immunoreactivity for cytokeratin and mesothelial and/or epithelial markers are proposed. Localized sarcomatoid mesotheliomas can only be diagnosed in the presence of spindle cell malignancies that exhibit immunoreactivity for cytokeratin and mesothelial markers and negative immunoreactivity for epithelial lesions, in patients that show no multifocal or diffuse pleural spread and no evidence for extrapleural lesions.

KW - Differential diagnosis

KW - Guidelines

KW - Pleomorphic carcinoma

KW - Sarcomatoid mesothelioma

KW - Spindle cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85028813468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028813468&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2017.07.015

DO - 10.1016/j.humpath.2017.07.015

M3 - Article

VL - 67

SP - 160

EP - 168

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -